Gyon Technologies Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Gyon Technologies Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,834	Closed	-$750K	–	96
2022 Q4	$750K	Buy	16,834 +5,881	+54%	+$210K	0.28%	115
2022 Q3	$308K	Sell	10,953 -2,965	-21%	-$90.9K	0.1%	272
2022 Q2	$375K	Buy	13,918 +3,366	+32%	+$97.8K	0.11%	217
2022 Q1	$359K	Sell	10,552 -7,836	-43%	-$250K	0.25%	139
2021 Q4	$711K	Sell	18,388 -17,376	-49%	-$757K	0.13%	213
2021 Q3	$1.93M	Buy	+35,764	New	+$1.68M	0.52%	63

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Gyon Technologies Capital Management's CLDX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 16,834 shares — an estimated $750K sold.

Gyon Technologies Capital Management first reported a position in CLDX in Q3 2021 and held it in 6 quarters. The position peaked at $1.93M in Q3 2021. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

Gyon Technologies Capital Management reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
Gyon Technologies Capital Management sold 16,834 Celldex Therapeutics shares in Q1 2023, an estimated $750K.
Gyon Technologies Capital Management first reported a position in Celldex Therapeutics in Q3 2021 and held it in 6 quarters.
Gyon Technologies Capital Management's Celldex Therapeutics position peaked at $1.93M in Q3 2021.
161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.